Even though the use of miRNAs in a clinical setting is currently limited, the recent FDA approval of siRNA for the treatment of the peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis is promising for ncRNA therapy [460]. Here, TTR is linked to peripheral nervous system disorder.